EpiPen Litigation

Severe allergy sufferers and their families are being forced to pay unconscionable prices for Mylan’s EpiPen injectors. Our trial lawyers are actively pursuing class-action claims to hold Mylan accountable for its cutthroat sales and marketing tactics.

If you’re on a phone, scroll down to fill out the form and start your claim today.

Severe Allergy Sufferers

With the EpiPen, Mylan has victimized the most vulnerable with enormous price increases.

Mylan EpiPen

The EpiPen sold for $57 when Mylan purchased it in 2007. Since then, the corporation has moved its headquarters overseas to avoid paying U.S. taxes and has increased the cost of the EpiPen to more than $600. That’s an increase of more than 1,000 percent. There is a word for this kind of corporate behavior: greed.

In response to public outcry about the outrageous price increase, Mylan has announced plans to issue a $300 generic version of the EpiPen. Talk about too little, too late. This company’s generic version of its own product would still be more than three times the price of the EpiPen in 2007.

Families of Children with Severe Allergies

Severe Allergy EpiPen Sufferers

The EpiPen is essential for families of children with severe allergies, where exposure to trace amounts of peanuts or a random insect bite can trigger a life-threatening allergic reaction. This tax-dodging pharmaceutical giant knows that families with children suffering severe allergies will do anything to find a way to pay these predatory prices when their kids’ health and safety are at stake.

Mylan’s greed is on full display with a children’s product called EpiPen Jr. It has a retail price of more than $700 even though it contains half the dosage and is meant for children. Those unable to pay these inflated prices have resorted to using manual syringes to inject a dose of epinephrine, which doctors warn comes with a risk of injecting the wrong dosage.

Take Action Against Mylan

Mylan executives and corporate lobbyists have not been swayed by threats from government regulators and politicians, but our trial team will not let this systematic and deliberate price-gouging continue.

Contact us using the form on this page if you have purchased, including through insurance, an EpiPen since January 1, 2009.

Click here to view the press release about the EpiPen class-action lawsuit.